Mingkai Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mingkai Zhang has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Hao-Jie Chen
State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China
4 shared publications - Ni Shu
State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University, Beijing, China
4 shared publications - Ying Han
Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 100053, China
4 shared publications - Weijie Huang
College of Artificial Intelligence, Nanjing University of Aeronautics and Astronautics, the Key Laboratory of Brain-Machine Intelligence Technology, Ministry of Education, Nanjing, China.
3 shared publications - Guanqun Chen
Department of Neurology, XuanWu Hospital of Capital Medical University, Beijing, 100053, China
2 shared publications Guolin Ma
Department of Radiology, China-Japan Friendship Hospital, BeiJing, China
2 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2705
Shared Gut Microbial and Functional Signatures Linking Parkinson’s Disease and Type 2 Diabetes Revealed by Function-Anchored Metagenomics
Parkinson’s disease (PD) and type 2 diabetes mellitus (T2DM) exhibit increasing comorbidity, yet the shared contribution of gut microbiota remains unclear. To investigate parallel microbial and functional alterations underlying PD, T2DM, and PD with diabetes (PDDM), we performed fecal metagenomic sequencing in 156 PD, 41 T2DM, and 44 PD with diabetes (PDDM) patients and 83 healthy controls (HC). PD and T2DM showed highly concordant microbial shifts, with 22 genera and 91 species consistently altered across disease groups compared with HC. Functional enrichment highlighted common perturbations in taurine and hypotaurine metabolism, retinol metabolism, the hypoxia-inducible factor-1 (HIF-1) pathway, and xenobiotic degradation, implicating disrupted oxidative stress responses, neuro-metabolic regulation, and detoxification. Key taxa, including Limosilactobacillus fermentum, Lactobacillus porci, and Lactobacillus delbrueckii, were increased and showed moderate positive correlations (|ρ| ≥ 0.3) with antioxidant/retinol–HIF-1, taurine–hypotaurine, and xenobiotic degradation pathways. Bifidobacterium breve (unadjusted analysis) was increased in PD and further enriched in PDDM, correlating with multiple beneficial pathways. Bifidobacterium simiarum (covariate-adjusted analyses) showed the broadest positive pathway associations, while selected Bacteroides species (e.g., B. acidifaciens) exhibited negative correlations with insulin-resistance pathways and positive correlations with steroid hormone biosynthesis. By contrast, Butyricimonas vaginalis showed negative correlations with HIF-1 and insulin signaling and with cytochrome P450-related drug metabolism. These findings provide the first systematic evidence of parallel taxonomic and functional dysbiosis in PD and T2DM, supporting gut microbiota as a shared mediator and potential therapeutic target in comorbidity.
- 27 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (12) , 2705
Open AccessShared Gut Microbial and Functional Signatures Linking Parkinson’s Disease and Type 2 Diabetes Revealed by Function-Anchored Metagenomics
Parkinson’s disease (PD) and type 2 diabetes mellitus (T2DM) exhibit increasing comorbidity, yet the shared contribution of gut microbiota remains unclear. To investigate parallel microbial and functional alterations underlying PD, T2DM, and PD with diabetes (PDDM), we performed fecal metagenomic sequencing in 156 PD, 41 T2DM, and 44 PD with diabetes (PDDM) patients and 83 healthy controls (HC). PD and T2DM showed highly concordant microbial shifts, with 22 genera and 91 species consistently altered across disease groups compared with HC. Functional enrichment highlighted common perturbations in taurine and hypotaurine metabolism, retinol metabolism, the hypoxia-inducible factor-1 (HIF-1) pathway, and xenobiotic degradation, implicating disrupted oxidative stress responses, neuro-metabolic regulation, and detoxification. Key taxa, including Limosilactobacillus fermentum, Lactobacillus porci, and Lactobacillus delbrueckii, were increased and showed moderate positive correlations (|ρ| ≥ 0.3) with antioxidant/retinol–HIF-1, taurine–hypotaurine, and xenobiotic degradation pathways. Bifidobacterium breve (unadjusted analysis) was increased in PD and further enriched in PDDM, correlating with multiple beneficial pathways. Bifidobacterium simiarum (covariate-adjusted analyses) showed the broadest positive pathway associations, while selected Bacteroides species (e.g., B. acidifaciens) exhibited negative correlations with insulin-resistance pathways and positive correlations with steroid hormone biosynthesis. By contrast, Butyricimonas vaginalis showed negative correlations with HIF-1 and insulin signaling and with cytochrome P450-related drug metabolism. These findings provide the first systematic evidence of parallel taxonomic and functional dysbiosis in PD and T2DM, supporting gut microbiota as a shared mediator and potential therapeutic target in comorbidity.
- Open Access
- 23 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121550
Multimodal integration of plasma biomarkers, MRI, and genetic risk to predict cerebral amyloid burden in Alzheimer’s disease
- 23 October 2025
- Published by Elsevier in NeuroImage
- Vol. 322, 121550
Open AccessMultimodal integration of plasma biomarkers, MRI, and genetic risk to predict cerebral amyloid burden in Alzheimer’s disease
- Open Access
- 21 October 2025
- Published by Springer Nature in Genome Medicine
- Vol. 17 (1) , 1-14
Polygenic risk for Alzheimer’s disease in healthy aging: age-related and APOE-driven effects on brain structures and cognition
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and cognitive decline with age. The genetic architecture of AD involves multiple loci, including the apolipoprotein E gene (APOE). The polygenic risk scores for AD (AD-PRS) provide a comprehensive genome-wide assessment of AD risk, yet their age-related effects on brain structures and cognitive function in cognitively unimpaired individuals remain largely undefined. We analyzed cognitively unimpaired, genetically unrelated Caucasians from the UK Biobank (N = 21,236, 64.5 ± 7.6 years). AD-PRS was derived using a Bayesian approach incorporating approximately 5 million genetic variants (UK Biobank’s standard PRS). Brain structures were measured with regional gray matter (GM) volumes and tract-wise microstructural white matter (WM) integrity. Cognitive performance was evaluated with executive function, visuospatial function, reasoning, and memory. Sliding window analyses were performed to investigate age-related polygenic effects on brain structures, and mediation analyses tested whether structural changes mediated the gene–cognition relationship across different age groups. Analyses were replicated using two custom PRSs—one including APOE and the other excluding APOE regions—calculated with the clumping-and-thresholding approach. High AD-PRS was associated with accelerated GM atrophy (particularly in the hippocampus, thalamus, and parahippocampus), increased cerebral ventricular volume, and reduced WM integrity (especially in the fornix, cingulum, and superior fronto-occipital fasciculus). These polygenic effects demonstrated significant age-related amplification (pBonf < 0.05), with the strongest effects in individuals aged ≥ 75. Elevated AD-PRS was linked to lower cognitive performance across aging, especially in executive function, reasoning, and memory, which were significantly mediated by structural brain changes in subcortical and posterior limbic regions and their WM connections, predominantly in late aging (p < 0.05). Sensitivity analyses confirmed the robustness of these findings, emphasizing the dominant contribution of APOE, while also identifying age-specific effects from non-APOE variants. High polygenic risk for AD may be associated with accelerated cognitive decline in healthy aging, mediated by structural changes within hippocampal-thalamic regions and their connecting WM tracts. We provide insights into the early pathogenesis of AD and support the potential for age-targeted screening and early intervention for individuals at high genetic risk.
- 21 October 2025
- Published by Springer Nature in Genome Medicine
- Vol. 17 (1) , 1-14
Open AccessPolygenic risk for Alzheimer’s disease in healthy aging: age-related and APOE-driven effects on brain structures and cognition
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and cognitive decline with age. The genetic architecture of AD involves multiple loci, including the apolipoprotein E gene (APOE). The polygenic risk scores for AD (AD-PRS) provide a comprehensive genome-wide assessment of AD risk, yet their age-related effects on brain structures and cognitive function in cognitively unimpaired individuals remain largely undefined. We analyzed cognitively unimpaired, genetically unrelated Caucasians from the UK Biobank (N = 21,236, 64.5 ± 7.6 years). AD-PRS was derived using a Bayesian approach incorporating approximately 5 million genetic variants (UK Biobank’s standard PRS). Brain structures were measured with regional gray matter (GM) volumes and tract-wise microstructural white matter (WM) integrity. Cognitive performance was evaluated with executive function, visuospatial function, reasoning, and memory. Sliding window analyses were performed to investigate age-related polygenic effects on brain structures, and mediation analyses tested whether structural changes mediated the gene–cognition relationship across different age groups. Analyses were replicated using two custom PRSs—one including APOE and the other excluding APOE regions—calculated with the clumping-and-thresholding approach. High AD-PRS was associated with accelerated GM atrophy (particularly in the hippocampus, thalamus, and parahippocampus), increased cerebral ventricular volume, and reduced WM integrity (especially in the fornix, cingulum, and superior fronto-occipital fasciculus). These polygenic effects demonstrated significant age-related amplification (pBonf < 0.05), with the strongest effects in individuals aged ≥ 75. Elevated AD-PRS was linked to lower cognitive performance across aging, especially in executive function, reasoning, and memory, which were significantly mediated by structural brain changes in subcortical and posterior limbic regions and their WM connections, predominantly in late aging (p < 0.05). Sensitivity analyses confirmed the robustness of these findings, emphasizing the dominant contribution of APOE, while also identifying age-specific effects from non-APOE variants. High polygenic risk for AD may be associated with accelerated cognitive decline in healthy aging, mediated by structural changes within hippocampal-thalamic regions and their connecting WM tracts. We provide insights into the early pathogenesis of AD and support the potential for age-targeted screening and early intervention for individuals at high genetic risk.
- 7 March 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (8) , 2929-2940
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging
Purpose Brain structure-function coupling (SFC), which reflects the degree to which anatomical structure supports neural function, is an emerging imaging marker in neurodegenerative diseases. However, its pathological underpinnings in Alzheimer’s disease (AD) remain poorly understood. This study aimed to examine the association among amyloid pathology, SFC disruption and cognitive decline. Methods We included 173 participants from the SILCODE cohort, comprising cognitively unimpaired (CU) and cognitively impaired (CI) individuals. Amyloid pathology was quantified using [18F]-florbetapir PET standardized uptake value ratios (SUVR). Structural connectivity (SC) was derived from diffusion-weighted MRI with probabilistic tractography, while functional connectivity (FC) was calculated from resting-state functional MRI. SFC was defined as the coefficient of determination from linear models predicting FC based on SC at regional level. Linear regression and mediation analyses were conducted to assess relationships between amyloid pathology, SFC, and multiple cognitive performances. Results Compared to CU individuals, CI participants exhibited increased regional SFC primarily within the default mode network regions (p < 0.05). In CI participants, amyloid pathology correlated with SFC across occipital lobe, precuneus and temporoparietal regions, which was specific by APOE ε4 status (p < 0.05). Mediation analyses revealed that SFC partially mediated the relationship between amyloid pathology and cognitive impairment (abMoCA−B = -0.14, 95% CI [-0.27, -0.02]). Similar findings were replicated with plasma markers. Conclusion Amyloid pathology may underlie SFC disruptions, contributing to cognitive decline in AD. These findings suggest that SFC may serve as a potential biomarker for amyloid-related neurodegeneration and cognitive impairment. Trial registration The SILCODE is listed on the ClinicalTrials.gov registry (SILCODE: NCT03370744).
- 7 March 2025
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (8) , 2929-2940
Amyloid pathology related to aberrant structure-function coupling of brain networks in Alzheimer’s disease: insights from [18F]-florbetapir PET imaging
Purpose Brain structure-function coupling (SFC), which reflects the degree to which anatomical structure supports neural function, is an emerging imaging marker in neurodegenerative diseases. However, its pathological underpinnings in Alzheimer’s disease (AD) remain poorly understood. This study aimed to examine the association among amyloid pathology, SFC disruption and cognitive decline. Methods We included 173 participants from the SILCODE cohort, comprising cognitively unimpaired (CU) and cognitively impaired (CI) individuals. Amyloid pathology was quantified using [18F]-florbetapir PET standardized uptake value ratios (SUVR). Structural connectivity (SC) was derived from diffusion-weighted MRI with probabilistic tractography, while functional connectivity (FC) was calculated from resting-state functional MRI. SFC was defined as the coefficient of determination from linear models predicting FC based on SC at regional level. Linear regression and mediation analyses were conducted to assess relationships between amyloid pathology, SFC, and multiple cognitive performances. Results Compared to CU individuals, CI participants exhibited increased regional SFC primarily within the default mode network regions (p < 0.05). In CI participants, amyloid pathology correlated with SFC across occipital lobe, precuneus and temporoparietal regions, which was specific by APOE ε4 status (p < 0.05). Mediation analyses revealed that SFC partially mediated the relationship between amyloid pathology and cognitive impairment (abMoCA−B = -0.14, 95% CI [-0.27, -0.02]). Similar findings were replicated with plasma markers. Conclusion Amyloid pathology may underlie SFC disruptions, contributing to cognitive decline in AD. These findings suggest that SFC may serve as a potential biomarker for amyloid-related neurodegeneration and cognitive impairment. Trial registration The SILCODE is listed on the ClinicalTrials.gov registry (SILCODE: NCT03370744).
- Open Access
- 27 July 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (9) , 5926-5939
Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts
INTRODUCTION: Subjective cognitive decline (SCD) in amyloid‐positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.METHODS: Eight hundred twenty‐one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed‐effects models.RESULTS: In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ− participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.DISCUSSION: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.Highlights: SCD in amyloid‐positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.
- 27 July 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (9) , 5926-5939
Open AccessAmyloid and SCD jointly predict cognitive decline across Chinese and German cohorts
INTRODUCTION: Subjective cognitive decline (SCD) in amyloid‐positive (Aβ+) individuals was proposed as a clinical indicator of Stage 2 in the Alzheimer's disease (AD) continuum, but this requires further validation across cultures, measures, and recruitment strategies.METHODS: Eight hundred twenty‐one participants from SILCODE and DELCODE cohorts, including normal controls (NC) and individuals with SCD recruited from the community or from memory clinics, underwent neuropsychological assessments over up to 6 years. Amyloid positivity was derived from positron emission tomography or plasma biomarkers. Global cognitive change was analyzed using linear mixed‐effects models.RESULTS: In the combined and stratified cohorts, Aβ+ participants with SCD showed steeper cognitive decline or diminished practice effects compared with NC or Aβ− participants with SCD. These findings were confirmed using different operationalizations of SCD and amyloid positivity, and across different SCD recruitment settings.DISCUSSION: Aβ+ individuals with SCD in German and Chinese populations showed greater global cognitive decline and could be targeted for interventional trials.Highlights: SCD in amyloid‐positive (Aβ+) participants predicts a steeper cognitive decline. This finding does not rely on specific SCD or amyloid operationalization. This finding is not specific to SCD patients recruited from memory clinics. This finding is valid in both German and Chinese populations. Aβ+ older adults with SCD could be a target population for interventional trials.
- Open Access
- 15 March 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (3) , 281
APOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial
Objective: To explore the association between the apolipoprotein E (APOE) genotype and objectively assessed cognitive function. Methods: In this cross-sectional study, 537 participants underwent a neuropsychological assessment for cognitive function and blood testing for APOE genotype. Based on cognitive test results, participants were stratified into two cohorts: Cognitively Unimpaired participants (CU) and Cognitively Impaired participants (CI). The CI group was further divided into Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). Furthermore, we conducted age stratification, categorizing participants into three age groups: age 1: 75 years. We assessed the disparities in cognitive function associated with ε4 carrier status across different age brackets. Plasma amyloid-β levels were measured in a cohort of 294 participants to investigate potential interactions involving ε4 carrier status, diagnosis, sex, or plasma markers. Results: The APOE genotypic distribution among the 537 participants was characterized as follows: ε2/ε2 (5 participants), ε2/ε3 (67), ε2/ε4 (13), ε3/ε3 (330), ε3/ε4 (113), and ε4/ε4 (9). Allele frequencies were: ε3 at 78.21%, ε4 at 13.41%, and ε2 at 8.38%. Notably, the ε4 carrier frequency was markedly elevated in the AD group at 81.8% when compared to MCI at 32.8% and CU at 21.3% (p < 0.05). Within the Cognitively Unimpaired (CU) cohort, the sole discernible contrast between ε4+ and ε4− emerged in STT-B (p < 0.05). Within the CI group, ε4 carriers showed statistically poorer scores as compared to non-ε4 carriers in several cognitive tests (p < 0.05). Age stratification result revealed that, among ε4 carriers, cognitive function scores within the age 3 group were significantly inferior to those of age 1 and age 2 groups (p < 0.05). Plasma amyloid-β detection was applied to the 294 participants. We tested plasma amyloid-β (Aβ42) and plasma amyloid-β (Aβ40) levels and calculated the Aβ42/Aβ40 ratio. We found that among female ε4 carriers, both Aβ42 and the Aβ42/Aβ40 ratio were notably lower than their male counterparts (p < 0.05). Conclusions: The ε3/ε3 was the most prevalent among participants, succeeded by ε3/ε4 and ε2/ε3. The least prevalent were ε2/ε4, ε4/ε4, and ε2/ε2 genotypes. The ε3 was predominant, followed by the ε4 and ε2. Individuals with the ε4 allele exhibited significant cognitive impairment, with an especially high prevalence in AD group at 81.8%. The study unveils a pronounced correlation between the ε4 allele and cognitive deficits, implying its potential role in the advancement and severity of cognitive disorders, notably Alzheimer’s disease. Cognitive function declines with age in individuals carrying the ε4, and women are more affected by ε4.
- 15 March 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (3) , 281
Open AccessAPOEε4 Carriers Exhibit Objective Cognitive Deficits: A Cross-Sectional Study in a Single Center Trial
Objective: To explore the association between the apolipoprotein E (APOE) genotype and objectively assessed cognitive function. Methods: In this cross-sectional study, 537 participants underwent a neuropsychological assessment for cognitive function and blood testing for APOE genotype. Based on cognitive test results, participants were stratified into two cohorts: Cognitively Unimpaired participants (CU) and Cognitively Impaired participants (CI). The CI group was further divided into Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD). Furthermore, we conducted age stratification, categorizing participants into three age groups: age 1: 75 years. We assessed the disparities in cognitive function associated with ε4 carrier status across different age brackets. Plasma amyloid-β levels were measured in a cohort of 294 participants to investigate potential interactions involving ε4 carrier status, diagnosis, sex, or plasma markers. Results: The APOE genotypic distribution among the 537 participants was characterized as follows: ε2/ε2 (5 participants), ε2/ε3 (67), ε2/ε4 (13), ε3/ε3 (330), ε3/ε4 (113), and ε4/ε4 (9). Allele frequencies were: ε3 at 78.21%, ε4 at 13.41%, and ε2 at 8.38%. Notably, the ε4 carrier frequency was markedly elevated in the AD group at 81.8% when compared to MCI at 32.8% and CU at 21.3% (p < 0.05). Within the Cognitively Unimpaired (CU) cohort, the sole discernible contrast between ε4+ and ε4− emerged in STT-B (p < 0.05). Within the CI group, ε4 carriers showed statistically poorer scores as compared to non-ε4 carriers in several cognitive tests (p < 0.05). Age stratification result revealed that, among ε4 carriers, cognitive function scores within the age 3 group were significantly inferior to those of age 1 and age 2 groups (p < 0.05). Plasma amyloid-β detection was applied to the 294 participants. We tested plasma amyloid-β (Aβ42) and plasma amyloid-β (Aβ40) levels and calculated the Aβ42/Aβ40 ratio. We found that among female ε4 carriers, both Aβ42 and the Aβ42/Aβ40 ratio were notably lower than their male counterparts (p < 0.05). Conclusions: The ε3/ε3 was the most prevalent among participants, succeeded by ε3/ε4 and ε2/ε3. The least prevalent were ε2/ε4, ε4/ε4, and ε2/ε2 genotypes. The ε3 was predominant, followed by the ε4 and ε2. Individuals with the ε4 allele exhibited significant cognitive impairment, with an especially high prevalence in AD group at 81.8%. The study unveils a pronounced correlation between the ε4 allele and cognitive deficits, implying its potential role in the advancement and severity of cognitive disorders, notably Alzheimer’s disease. Cognitive function declines with age in individuals carrying the ε4, and women are more affected by ε4.
- Open Access
- 27 February 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-9
Gait impairment-related axonal degeneration in Parkinson’s disease by neurite orientation dispersion and density imaging
Microstructural alterations in the brain networks of Parkinson’s disease (PD) patients are correlated with gait impairments. Evaluate microstructural alterations in the white matter (WM) fiber bundle tracts using neurite orientation dispersion and density imaging (NODDI) technique in PD versus healthy controls (HC). In this study, 24 PD patients and 29 HC were recruited. NODDI and high-resolution 3D structural images were acquired for each participant. The NODDI indicators, including the intracellular neurite density index (NDI), orientation dispersion index (ODI), and isotropic volume fraction (ISO), were compared between the two groups. Diffusion-weighted (DW) images were preprocessed using MRtrix 3.0 software and the orientation distribution function to trace the main nerve fiber tracts in PD patients. Quantitative gait and clinical assessment scales were used to compare the medication “ON” and “OFF” states of PD patients. The NDI, ODI, and ISO values of the WM fiber bundles were significantly higher in PD patients compared to HC. Fiber bundles, including the anterior thalamic radiation, corticospinal tract, superior longitudinal fasciculus, forceps major, cingulum, and inferior longitudinal fasciculus, were found to be significantly affected in PD. The NDI changes of PD patients were well correlated with stride lengths in the “ON” state; ODI changes were correlated with the stride time in the “ON” and “OFF” states and ISO changes were correlated with the stride time and cadence in the “ON” state. In conclusion, combination of NODDI technique and gait parameters can help detect gait impairment in PD patients early and accurately.
- 27 February 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-9
Open AccessGait impairment-related axonal degeneration in Parkinson’s disease by neurite orientation dispersion and density imaging
Microstructural alterations in the brain networks of Parkinson’s disease (PD) patients are correlated with gait impairments. Evaluate microstructural alterations in the white matter (WM) fiber bundle tracts using neurite orientation dispersion and density imaging (NODDI) technique in PD versus healthy controls (HC). In this study, 24 PD patients and 29 HC were recruited. NODDI and high-resolution 3D structural images were acquired for each participant. The NODDI indicators, including the intracellular neurite density index (NDI), orientation dispersion index (ODI), and isotropic volume fraction (ISO), were compared between the two groups. Diffusion-weighted (DW) images were preprocessed using MRtrix 3.0 software and the orientation distribution function to trace the main nerve fiber tracts in PD patients. Quantitative gait and clinical assessment scales were used to compare the medication “ON” and “OFF” states of PD patients. The NDI, ODI, and ISO values of the WM fiber bundles were significantly higher in PD patients compared to HC. Fiber bundles, including the anterior thalamic radiation, corticospinal tract, superior longitudinal fasciculus, forceps major, cingulum, and inferior longitudinal fasciculus, were found to be significantly affected in PD. The NDI changes of PD patients were well correlated with stride lengths in the “ON” state; ODI changes were correlated with the stride time in the “ON” and “OFF” states and ISO changes were correlated with the stride time and cadence in the “ON” state. In conclusion, combination of NODDI technique and gait parameters can help detect gait impairment in PD patients early and accurately.
- Open Access
- 12 January 2024
- Published by Wiley in Human Brain Mapping
- Vol. 45 (1) , e26566
Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum
Both plasma biomarkers and brain network topology have shown great potential in the early diagnosis of Alzheimer's disease (AD). However, the specific associations between plasma AD biomarkers, structural network topology, and cognition across the AD continuum have yet to be fully elucidated. This retrospective study evaluated participants from the Sino Longitudinal Study of Cognitive Decline cohort between September 2009 and October 2022 with available blood samples or 3.0‐T MRI brain scans. Plasma biomarker levels were measured using the Single Molecule Array platform, including β‐amyloid (Aβ), phosphorylated tau181 (p‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). The topological structure of brain white matter was assessed using network efficiency. Trend analyses were carried out to evaluate the alterations of the plasma markers and network efficiency with AD progression. Correlation and mediation analyses were conducted to further explore the relationships among plasma markers, network efficiency, and cognitive performance across the AD continuum. Among the plasma markers, GFAP emerged as the most sensitive marker (linear trend: t = 11.164, p = 3.59 × 10−24; quadratic trend: t = 7.708, p = 2.25 × 10−13; adjusted R2 = 0.475), followed by NfL (linear trend: t = 6.542, p = 2.9 × 10−10; quadratic trend: t = 3.896, p = 1.22 × 10−4; adjusted R2 = 0.330), p‐tau181 (linear trend: t = 8.452, p = 1.61 × 10−15; quadratic trend: t = 6.316, p = 1.05 × 10−9; adjusted R2 = 0.346) and Aβ42/Aβ40 (linear trend: t = −3.257, p = 1.27 × 10−3; quadratic trend: t = −1.662, p = 9.76 × 10−2; adjusted R2 = 0.101). Local efficiency decreased in brain regions across the frontal and temporal cortex and striatum. The principal component of local efficiency within these regions was correlated with GFAP (Pearson's R = −0.61, p = 6.3 × 10−7), NfL (R = −0.57, p = 6.4 × 10−6), and p‐tau181 (R = −0.48, p = 2.0 × 10−4). Moreover, network efficiency mediated the relationship between general cognition and GFAP (ab = −0.224, 95% confidence interval [CI] = [−0.417 to −0.029], p = .0196 for MMSE; ab = −0.198, 95% CI = [−0.42 to −0.003], p = .0438 for MOCA) or NfL (ab = −0.224, 95% CI = [−0.417 to −0.029], p = .0196 for MMSE; ab = −0.198, 95% CI = [−0.42 to −0.003], p = .0438 for MOCA). Our findings suggest that network efficiency mediates the association between plasma biomarkers, specifically GFAP and NfL, and cognitive performance in the context of AD progression, thus highlighting the potential utility of network‐plasma approaches for early detection, monitoring, and intervention strategies in the management of AD.
- 12 January 2024
- Published by Wiley in Human Brain Mapping
- Vol. 45 (1) , e26566
Open AccessRelationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum
Both plasma biomarkers and brain network topology have shown great potential in the early diagnosis of Alzheimer's disease (AD). However, the specific associations between plasma AD biomarkers, structural network topology, and cognition across the AD continuum have yet to be fully elucidated. This retrospective study evaluated participants from the Sino Longitudinal Study of Cognitive Decline cohort between September 2009 and October 2022 with available blood samples or 3.0‐T MRI brain scans. Plasma biomarker levels were measured using the Single Molecule Array platform, including β‐amyloid (Aβ), phosphorylated tau181 (p‐tau181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL). The topological structure of brain white matter was assessed using network efficiency. Trend analyses were carried out to evaluate the alterations of the plasma markers and network efficiency with AD progression. Correlation and mediation analyses were conducted to further explore the relationships among plasma markers, network efficiency, and cognitive performance across the AD continuum. Among the plasma markers, GFAP emerged as the most sensitive marker (linear trend: t = 11.164, p = 3.59 × 10−24; quadratic trend: t = 7.708, p = 2.25 × 10−13; adjusted R2 = 0.475), followed by NfL (linear trend: t = 6.542, p = 2.9 × 10−10; quadratic trend: t = 3.896, p = 1.22 × 10−4; adjusted R2 = 0.330), p‐tau181 (linear trend: t = 8.452, p = 1.61 × 10−15; quadratic trend: t = 6.316, p = 1.05 × 10−9; adjusted R2 = 0.346) and Aβ42/Aβ40 (linear trend: t = −3.257, p = 1.27 × 10−3; quadratic trend: t = −1.662, p = 9.76 × 10−2; adjusted R2 = 0.101). Local efficiency decreased in brain regions across the frontal and temporal cortex and striatum. The principal component of local efficiency within these regions was correlated with GFAP (Pearson's R = −0.61, p = 6.3 × 10−7), NfL (R = −0.57, p = 6.4 × 10−6), and p‐tau181 (R = −0.48, p = 2.0 × 10−4). Moreover, network efficiency mediated the relationship between general cognition and GFAP (ab = −0.224, 95% confidence interval [CI] = [−0.417 to −0.029], p = .0196 for MMSE; ab = −0.198, 95% CI = [−0.42 to −0.003], p = .0438 for MOCA) or NfL (ab = −0.224, 95% CI = [−0.417 to −0.029], p = .0196 for MMSE; ab = −0.198, 95% CI = [−0.42 to −0.003], p = .0438 for MOCA). Our findings suggest that network efficiency mediates the association between plasma biomarkers, specifically GFAP and NfL, and cognitive performance in the context of AD progression, thus highlighting the potential utility of network‐plasma approaches for early detection, monitoring, and intervention strategies in the management of AD.